 Context Therapeutics NASDAQ:CNTX Inc has reported results for the second quarter that revealed ample cash on hand, giving the company scope to advance its pipeline programs. As of June 30, 2022, the Philadelphia-based womens oncology company developing treatments for breast and gynecological cancers, had cash, equivalents, and restricted cash which totaled 42.9 million. 